REG - RUA Life Sciences - Holding(s) in Company
RNS Number : 4480KRUA Life Sciences PLC04 January 2021
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are at- tachedii:
RUA Life Sciences Plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name
Walker Crips Investment Management
City and country of registered office (if applicable)
London, United Kingdom
4. Full name of shareholder(s) (if different from 3.)v
Name
W B Nominees
City and country of registered office (if applicable)
Romford, United Kingdom
5. Date on which the threshold was crossed or reachedvi:
31/12/2020
6. Date on which issuer notified (DD/MM/YYYY):
04/01/2021
7. Total positions of person(s) subject to the notification obligation
% of voting rights at- tached to shares (to- tal of 8. A)
% of voting rights through financial instru- ments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights of is- suervii
Resulting situation on the date on which threshold was crossed or reached
8.65%
8.65%
22,184,797
Position of previous notification (if applicable)
11.98%
11.98%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of shares
ISIN code (if possible)
Number of voting rightsix
% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB0033360586
1,917,973
8.65%
SUBTOTAL 8. A
1,917,973
8.65%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial in- strument
Expiration datex
Exercise/ Conversion Periodxi
Number of voting rights that may be acquired if the instrument is exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expiration datex
Exercise/ Conversion Pe- riod xi
Physical or cash settlementxii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)
X
Namexv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial in- struments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
Walker Crips Group Plc
Walker Crips Investment Management Limited
W B Nominees Plc
8.65%
8.65%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi
Place of completion
Walker Crips Investment Management
Date of completion
04/01/2021
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDHOLUPUAGGUPGGGC
Recent news on Rua Life Sciences
See all newsREG - RUA Life Sciences - Change of Registered Office
AnnouncementREG - RUA Life Sciences - Trading Update
AnnouncementREG - RUA Life Sciences - Director/PDMR Shareholding
AnnouncementREG - RUA Life Sciences - Acquisition Update
AnnouncementREG - RUA Life Sciences - New Supply Agreement
Announcement